Skip to content

Microbiota of the Respiratory Flora in Children With Cystic Fibrosis During the First Year of Life

Microbiota of the Respiratory Flora in Children With Cystic Fibrosis During the First Year of Life

Status
Withdrawn
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00977158
Enrollment
0
Registered
2009-09-15
Start date
2011-05-31
Completion date
Unknown
Last updated
2015-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystic Fibrosis

Keywords

Cystic Fibrosis, Microbiota, upper respiratory tract, 16S rRNA sequence analysis, Staphylococcus aureus, Pseudomonas aeruginosa, Burkholderia cepacia, Haemophilus influenzae, Streptococcus pneumoniae

Brief summary

The goal of this study is characterize the changes in bacterial diversity of the upper respiratory tracts of infants with cystic fibrosis (CF). Another goal is to determine when CF patients become colonized with pathogenic bacteria that are responsible for the lethal lung damage in children with CF. Ten subjects will be recruited into the study. Throat swabs will be collected at 6-8 weeks of age, 3 months, 6 months, 9 months, and 12 months of age in order to chart any changes in the bacterial populations of the respiratory tract. Clinical data will also be collected to evaluate the possible influence of external factors on changes in the microbial communities. This study will provide preliminary data on whether probiotics can eradicate the colonization of the respiratory tract by pathogenic bacteria.

Interventions

PROCEDUREThroat Swab

Swabs will be moistened in sterile 0.9% sodium chloride solution and rotated in the throat and processed for bacterial cultures and for bacterial DNA extraction.

Sponsors

Tufts Medical Center
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
1 Days to 3 Months
Healthy volunteers
No

Inclusion criteria

* Male and female subjects, newborn to age 3 months * Have a diagnosis of cystic fibrosis (Diagnosis of CF will be based on either a positive sweat chloride of \>60 mEq/L or the identification of two detectable mutations associated with CF * Parent/guardian plans to have follow-up care for approximately one year at designated CF clinic * Parent/guardian provides informed consent to participate in the study

Exclusion criteria

* Contraindications for obtaining oropharyngeal swabs

Design outcomes

Primary

MeasureTime frame
To characterize the microbial ecology and changes in bacterial diversity of the oropharynx in a cohort of children with CF during the first year of life using 16S rRNA sequence analysis6-8 weeks of age, 3 months, 6 months, 9 months, and 12 months of age
To describe the clinical variables that may be associated with changes in microbial ecology in children with cystic fibrosis over the first year of life6-8 weeks of age, 3 months, 6 months, 9 months, and 12 months of age
To explore changes in the microbial ecology of the oropharynx in conjunction with Staphylococcus aureus colonization in children with CF6-8 weeks of age, 3 months, 6 months, 9 months, and 12 months of age

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026